Epineuron Receives 510(k) Clearance for Nerve Stimulator

Start
Epineuron Technologies, a Canada-based clinical-stage nerve care company developing a bioelectronic therapy for the treatment of injured peripheral nerves, announced on May 12 that it has received 510(k) clearance of its Evala® Nerve Stimulator from the U.S. Food and Drug Administration (FDA)….
By: Knobbe Martens
Previous Story

Government Defendant Wins Dismissal Due to Lack of Subject Matter Jurisdiction

Next Story

When the worm targets the assistant: Miasma turns AI coding agents into the trigger